# Allelica, Inc.

> Allelica is a genomics software company building the tools that move polygenic risk scores (PRS) out of the research lab and into routine clinical care. Its cloud platform lets labs and health systems develop, validate, and apply PRS across multiple ancestries, and its clinical test AbsoluteDx combines rare-variant (monogenic) and genome-wide (polygenic) risk in a single report. The company's stated priority is equity - building risk scores that work for patients regardless of genetic ancestry - and its multi-ancestry coronary artery disease work was cited in the 2026 ACC/AHA cardiovascular prevention guidelines.

- **Founded:** 2018
- **Headquarters:** San Francisco, California, United States
- **Founders:** Giordano Bottà (Co-founder & CEO), Paolo Di Domenico (Co-founder), George Busby (Co-founder)
- **Team size:** ~11 employees
- **Products:** Allelica PRS Platform (DISCOVER / VALIDATE / PREDICT), Ancestry-Specific PRS Laboratory-Developed Test (LDT), AbsoluteDx, 8 Billion Method
- **Notable:** Multi-ancestry coronary artery disease PRS study cited in the 2026 ACC/AHA cardiovascular prevention guidelines., Software licensed by Illumina., Selected by Baylor College of Medicine for clinical PRS implementation (2024).

## Products & services

- **Allelica PRS Platform (DISCOVER / VALIDATE / PREDICT)** — A cloud platform that streamlines the full polygenic risk score workflow: DISCOVER builds new PRS using four state-of-the-art algorithms in parallel to find the best predictive model; VALIDATE tests portability across ancestries; PREDICT applies the score to individual patient data.
- **Ancestry-Specific PRS Laboratory-Developed Test (LDT)** — A clinical-grade, ancestry-specific polygenic risk score test for common diseases including coronary artery disease, breast cancer, prostate cancer, Type 2 diabetes, and Alzheimer's disease.
- **AbsoluteDx** — A comprehensive clinical genetic test that combines monogenic (rare pathogenic variant) and polygenic risk assessment in a single solution, capturing the interplay between rare mutations and genome-wide risk.
- **8 Billion Method** — A method for modeling human genetic diversity without ancestry labels, improving PRS performance across diverse populations and reducing bias in genetic risk assessment. Presented at ASHG 2024.

## Achievements

- Multi-ancestry coronary artery disease PRS study cited in the 2026 ACC/AHA cardiovascular prevention guidelines.
- Software licensed by Illumina.
- Selected by Baylor College of Medicine for clinical PRS implementation (2024).
- Launched a CLIA-context ancestry-specific PRS laboratory-developed test across five major diseases.
- Introduced the '8 billion method' for label-free modeling of human genetic diversity at ASHG 2024.
- Published a health-economics study demonstrating cost savings from PRS in heart-attack prevention.

## Latest updates

- **2026-01** — Allelica's multi-ancestry CAD polygenic risk score study cited in the 2026 ACC/AHA guidelines.
- **2024-11** — Presented the '8 billion method' for modeling genetic diversity without ancestry labels at ASHG 2024.
- **2024-03** — Announced collaboration with Baylor College of Medicine for clinical PRS implementation.
- **2022-09** — Launched ancestry-specific PRS tests as a laboratory-developed test for common diseases.

## Links

- Website: https://allelica.com
- LinkedIn: https://www.linkedin.com/company/allelica
- Twitter/X: https://twitter.com/Allelica_PRS

---

Profile page: https://yespress.io/allelica-inc
Published by YesPress — https://yespress.io
Last updated: 2026-07-14